Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference
LONDON, May 12, 2021 – Freeline Therapeutics Holdings (Nasdaq: FRLN) announced participation in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 4:50 pm EDT. The event will include a webcast available in the Investors section of Freeline's website. Freeline focuses on developing AAV gene therapies for inherited diseases, with ongoing clinical programs targeting Hemophilia B and Fabry disease. The company aims to deliver one-time treatments that provide functional cures through its innovative gene therapy platform.
- None.
- None.
LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that senior management will participate in a Fireside Chat at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:50 pm EDT.
A webcast of the event will be available on the Investors section of the Freeline website. Senior management will also participate in virtual one-on-one meetings with investors at the conference.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.
Contact
David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947
FAQ
When is Freeline Therapeutics participating in the RBC Capital Markets Global Healthcare Conference?
Where can I watch the Freeline Therapeutics Fireside Chat?
What is the focus of Freeline Therapeutics as mentioned in the press release?
What clinical programs does Freeline Therapeutics have?
What is the goal of Freeline Therapeutics' gene therapies?
